Ventricular tachycardia exercise-induced

The hemodynamic effects of sotalol are related to its 3-adrenoceptor antagonist activity. Accordingly, decreases in resting heart rate and in exercise-induced tachycardia are seen in patients receiving sotalol. A modest reduction in systolic pressure and in cardiac output may occur. The reduction in cardiac output is a consequence of lowering the heart rate, since stroke volume is unaffected by sotalol treatment. In patients with normal ventricular function, cardiac output is maintained despite the decrease in heart rate because of the simultaneous increase in the stroke volume. 

Exercise-induced ventricular tachycardia in persons without overt cardiac disease is an example of delayed after-depolarizations and is characterized by an increase in intracellular ionized calcium. This type of arrhythmia is known to often respond well to which of the following combinations ... 

Lahat, H., Eldar, M., Levy-Nissenbaum, E., Bahan, T., Friedman, E., Khoury, A., Lorber, A., Kastner, D. L., Goldman, B., and Pras, E. (2001). Autosomal Recessive Catecholamine- or Exercise-Induced Polymorphic Ventricular Tachycardia Clinical Features and Assignment of the Disease Gene to Chromosome lpl3-21. Circulation 103(23) 2822-7. 

Laitinen, P. J., Swan, H., and Kontula, K. (2003). Molecular Genetics of Exercise-Induced Polymorphic Ventricular Tachycardia Identification of Three Novel Cardiac Ryanodine Receptor Mutations and Two Common Calsequestrin 2 Amino-Acid Polymorphisms. Eur J Hum Genet 11(11) 888-91. 

Vitullo RN, Wharton JM, Allen NB, Pritchett EL. Trazodone-related exercise-induced nonsustained ventricular tachycardia. Chest 1990 98(l) 247-8. 

The incidence of major adverse reactions to dipyridamole was determined in a multicenter retrospective study, involving 73 806 patients who underwent intravenous dipjridamole stress imaging in 59 hospitals and 19 countries (4). The main conclusion was that the risk of serious dipjridamole-induced adverse effects is very low, a conclusion that is in line with other reports (5), and comparable to that reported for exercise testing in a similar patient population. Combined major adverse events among the entire patient population included 7 cardiac deaths (0.95 per 10000), 13 non-fatal myocardial infarctions (1.76 per 10000), 6 non-fatal sustained ventricular dysrhythmias (0.81 per 10000) (ventricular tachycardia in 2 and ventricular fibrillation in 4), 9 transient cerebral ischemic attacks (1.22 per 10000), 1 stroke, and 9 severe cases of bronch-ospasm (1.22 per 10000). Minor non-cardiac adverse effects were less frequent among the elderly and more frequent in women and patients taking maintenance aspirin. 

---